One in two women with advanced ovarian cancer has an HRD-positive tumor
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The drug will be available in 600 hospitals and 105 DTPs
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Recommendation is based on pivotal data from the phase III POLARIX study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
